Stocks
Funds
Screener
Sectors
Watchlists
HARP

HARP - Harpoon Therapeutics Inc Stock Price, Fair Value and News

$23.01 
Market Closed

HARP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HARP Price Action

HARP RSI Chart

HARP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HARP Valuation

HARP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

HARP Fundamentals

HARP Revenue

HARP Earnings

HARP Profitability

HARP Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202334.6M46.5M37.3M0
202220.6M23.0M32.2M31.9M
202123.2M26.2M26.8M23.7M
20208.0M9.7M12.2M17.4M
20194.3M4.3M4.6M5.8M
20181.9M3.2M4.4M4.8M
2017000708.0K
HARP
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEharpoontx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES46